Workflow
CENTEK(000931)
icon
Search documents
引入近百家首店 中关村ART PARK大融城全面开业
Bei Jing Shang Bao· 2025-12-19 10:45
在整体运营方面,中关村ART PARK大融城引入精品生活超市、高端餐饮等业态。同时,项目引入跨界 品牌、潮流创意品牌等,以高比例的品牌首店矩阵出圈,带动区域消费升级。 北京商报讯(记者 王维祎)12月19日,中关村ART PARK大融城东区正式对外营业,这也意味着该项 目全部贯通,全面开业。 据悉,项目东区引入多家国际潮流品牌作为主力店,涵盖alexanderwang、MM6 Maison Margiela、 DIESEL、EXI.T、barbour等品牌,其中,barbour等为京西首店,Chili's等为北京首店,TORY BURCH、SHAKE SHACK、BUTTERFUL & CREAMOROUS黄油与面包等为海淀首店。除此以外,中 关村ART PARK大融城东区还引入了COACH概念店、gaga旗舰店、西西弗城市定制店等。 项目开业填补了区域的品牌短板。12月19日上午,中关村ART PARK大融城开始营业后,部分首店品牌 门店外就逐渐排起队伍。 目前,中关村ART PARK大融城布置了"线条小狗"冬日主题形象北京美陈首展、"年轮-螺旋纪年"-JIN ARTS肖进艺术定制主题装置、以及"鎏光星河" ...
中关村:下属公司盐酸羟考酮缓释片(10mg)上市许可申请获得受理
Xin Lang Cai Jing· 2025-12-19 10:41
中关村公告,下属公司北京华素制药股份有限公司于近日收到国家药品监督管理局签发的《受理通知 书》,盐酸羟考酮缓释片(规格:10mg)上市许可申请获得受理。盐酸羟考酮缓释片临床上用于治疗 严重到需要长期持续、每天按时使用阿片类药物治疗、且替代治疗不能充分缓解的疼痛。本品的原研药 于2021年在中国境内获批上市,目前境内已有2家仿制药获批上市,1家国内企业已递交上市许可申请, 北京华素是第4家提交本品仿制药上市许可申请的境内企业。截至本公告披露日,盐酸羟考酮缓释片项 目已累计投入研发费用1714.73万元。 ...
中关村(000931.SZ):盐酸丁螺环酮片一致性评价申报收到《受理通知书》
Ge Long Hui· 2025-12-19 08:24
Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the consistency evaluation application of the generic drug, Buprenorphine Hydrochloride Tablets [1] Group 1 - The drug Buprenorphine is the first non-benzodiazepine anxiolytic, acting as a 5-HT1A receptor agonist [1] - It selectively binds to the brain's 5-HT1A receptors, reducing excessive 5-HT activity associated with anxiety disorders [1] - The clinical advantage of this drug is its lack of dependency and withdrawal reactions, indicating a higher safety profile [1]
中关村:盐酸丁螺环酮片一致性评价申报获受理
Zhi Tong Cai Jing· 2025-12-19 08:17
Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the consistency evaluation application of the generic drug Buprenorphine Hydrochloride Tablets [1] Group 1: Company Developments - Beijing Huasu has received the acceptance notice for the application of Buprenorphine Hydrochloride Tablets (specifications: 5mg, 10mg) [1] - The drug Buprenorphine is the first non-benzodiazepine anxiolytic, acting as a 5-HT1A receptor agonist [1] Group 2: Drug Characteristics - Buprenorphine works by selectively binding to the brain's 5-HT1A receptors, reducing excessive 5-HT activity associated with anxiety disorders [1] - The main clinical advantage of Buprenorphine is its lack of drug dependence and withdrawal reactions, indicating a higher safety profile [1] - The indications for Buprenorphine Hydrochloride Tablets include various anxiety disorders [1]
中关村:“一种盐酸丁螺环酮的制备方法”取得专利证书
Mei Ri Jing Ji Xin Wen· 2025-12-19 08:09
截至发稿,中关村市值为37亿元。 每经AI快讯,中关村(SZ 000931,收盘价:4.96元)12月19日晚间发布公告称,近日,北京中关村科 技发展(控股)股份有限公司下属公司北京华素制药股份有限公司取得国家知识产权局颁发的发明专利 证书。专利名称为"一种盐酸丁螺环酮的制备方法"。 2025年1至6月份,中关村的营业收入构成为:生物医药占比80.15%,混凝土占比13.22%,养老健康占 比4.12%,其他占比2.51%。 每经头条(nbdtoutiao)——海南封关首日直击:为中国探路,全球最大自贸港如何重塑开放边界? (记者 曾健辉) ...
中关村(000931.SZ):盐酸丁螺环酮片一致性评价申报获受理
智通财经网· 2025-12-19 08:05
Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the consistency evaluation application of the generic drug Buprenorphine Hydrochloride Tablets [1] Group 1: Company Developments - Beijing Huasu has received the acceptance notice for the consistency evaluation of Buprenorphine Hydrochloride Tablets in 5mg and 10mg specifications [1] - Buprenorphine is the first non-benzodiazepine anxiolytic drug, acting as a 5-HT1A receptor agonist to reduce excessive 5-HT activity in anxiety disorders [1] Group 2: Product Characteristics - The clinical advantage of Buprenorphine is its lack of drug dependence and withdrawal reactions, indicating a higher safety profile [1] - The indications for Buprenorphine Hydrochloride Tablets include various anxiety disorders [1]
中 关 村(000931) - 关于下属公司北京华素盐酸丁螺环酮片一致性评价申报收到国家药品监督管理局《受理通知书》的公告
2025-12-19 08:00
关于下属公司北京华素盐酸丁螺环酮片一致性评价申报收到国家药品监督管理局《受理通知书》的公告 共 2 页 证券代码:000931 证券简称:中关村 公告编号:2025-141 北京中关村科技发展(控股)股份有限公司 关于下属公司北京华素盐酸丁螺环酮片一致性评价申报收到 药品名称:盐酸丁螺环酮片 注册商标:苏新® 剂型:片剂 规格:5mg、10mg 申请事项:境内生产药品一致性评价 申请人:北京华素制药股份有限公司 国家药品监督管理局《受理通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 北京中关村科技发展(控股)股份有限公司(以下简称:公司)下属公司 北京华素制药股份有限公司(以下简称:北京华素)于近日收到国家药品监督 管理局(以下简称:国家药监局)签发的《受理通知书》,盐酸丁螺环酮片(规 格:5mg、10mg)仿制药一致性评价申请获得受理,现将相关情况公告如下: 一、基本信息 北京华素的盐酸丁螺环酮片仿制药一致性评价申请获得国家药监局的受理, 标志着该品种一致性评价工作进入审评阶段,公司将积极推进后续相关工作, 如顺利获批将增加企业和市场竞争力, ...
中 关 村(000931) - 关于下属公司北京华素取得发明专利证书的公告
2025-12-19 08:00
关于下属公司北京华素取得发明专利证书的公告 共 1 页 注:专利权自授权公告之日起生效。专利权期限为二十年,自申请日起算。 上述发明专利不会对公司近期生产经营产生重大影响,但有利于进一步完善 公司知识产权保护体系,充分发挥自主知识产权优势,促进技术创新,形成持续 创新机制,提升公司的综合竞争力。敬请广大投资者注意投资风险。 备查文件 1、国家知识产权局颁发的发明专利证书。 特此公告 证券代码:000931 证券简称:中关村 公告编号:2025-140 北京中关村科技发展(控股)股份有限公司 关于下属公司北京华素取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 近日,北京中关村科技发展(控股)股份有限公司(以下简称:公司)下属 公司北京华素制药股份有限公司取得国家知识产权局颁发的发明专利证书,具体 情况如下: | 发明名称 | | | 专利申请日 | | 授权公告日 | | | 授权公告号 | 专利权人 | | | 专利号 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | - ...
中关村:下属公司盐酸丁螺环酮片一致性评价申请获受理
Xin Lang Cai Jing· 2025-12-19 08:00
Core Viewpoint - Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Zhongguancun, has received the Acceptance Notification from the National Medical Products Administration for the consistency evaluation application of the generic drug Buprenorphine Hydrochloride Tablets (specifications: 5mg, 10mg) [1] Group 1 - Buprenorphine is the first non-benzodiazepine anxiolytic drug [1] - In China, a total of four companies, including Beijing Huasu, have approved generic drugs for market entry, with two companies having passed the consistency evaluation for quality and efficacy of generic drugs [1]
中关村大融城东区开业
Bei Jing Shang Bao· 2025-12-19 07:15
Core Insights - The opening of the East District of Zhongguancun Dairong City marks a significant addition to high-quality consumption venues in the Zhongguancun area, featuring over 60 flagship stores and a park-style commercial layout to enhance consumer experiences [1] - The "2025 Beijing Consumption Season • Joyful Haidian" promotional activities aim to stimulate consumer spending through various discounts and unique events, contributing to the development of Beijing as an international consumption center [1] Group 1 - The East District of Zhongguancun Dairong City has introduced over 60 first stores, including 11 Beijing first stores, 26 western Beijing first stores, and 24 Haidian first stores, showcasing numerous international trendy brands and popular dining options [1] - The promotional activities include over 60 discount initiatives across more than 20 key shopping malls, featuring various forms such as discount promotions and point redemption [1] - Upcoming events during the New Year and Spring Festival will include countdowns and themed parties to create a festive shopping atmosphere [1] Group 2 - The "Cultural Season of Book Fragrance and Warm Winter" focuses on the integration of culture, commerce, tourism, and sports, launching projects like industrial tourism at Xiaomi Technology Park and VR digital experiences [2] - During the 14th Five-Year Plan period, Haidian District has added over 1.2 million square meters of commercial space and introduced 401 first stores, enhancing the local consumption capacity [2] - Future plans for Haidian District include optimizing consumer supply, deepening the integration of commerce and culture, and fostering new consumption scenarios involving artificial intelligence [2]